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Methods & Materials                                     
❏ Age of 7-8 week old C56BL/6 male and female 
mice fed for five consecutive weeks with the 
corresponding diets (either MCD or control).
❏ The CBG doses were divided into a vehicle, low 
(2.46 mg/kg), and high doses (24.6 mg/kg) 
❏ Body weights taken all weeks every Monday, 
Wednesday, and Friday; final body weights were 
recorded on the day of animal sacrifice. 
❏ Afterwards, the livers were also dissected, 
examined, weighed, and put into frozen media for 
staining. 
Discussion
Overall Conclusions: CBG could have implications in helping recover lost body and 
liver wight from the MCD induced diet. Low dosage of CBG was found to be beneficial 
in lessening tissue damage and fibrosis, while high dosage of CBG was found to 
negatively impact the liver by increasing tissue damage and fibrosis. 
Future Directions:
❏ Further run the same tests to reaffirm conclusions and have replicates of the data 
❏ Use a larger sample size (greater than the 6 sample size used here) to show the 
same effects across a large population 
❏ Investigate a diet besides MCD that induces all of the symptoms of NASH instead of 
a majority of the symptoms 
❏ Investigate the long term effects of CBG treatment on MCD diet by giving the 
treatment for a longer span of time  
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Summary 
❏ Average Food Consumption decreases significantly between Control High CBG 
groups and the MCD Control group
❏ Liver weights have significant difference between Control groups and MCD or 
MCD Low CBG groups
❏ Body weights are significantly different between all three Control groups with all 
three MCD groups
❏ When combining the liver weights to the body weights in a ratio, however, there 
is no statistically significant difference between overall Liver:Body Weight among 
any of the groups
❏ From the H&E staining, it is observed that L CBG treatment on either diet 
improves the overall liver tissue 
❏ For Oil-Red-O staining, there is more lipid accumulation in the MCD diet 
indicating the symptoms of NASH, but this is reduced with CBG treatment 
 
Figure 3. H&E staining (E) was performed for abnormal liver morphology and Oil-Red-O staining (F) was used for lipid droplets estimation within liver 
tissue. From the H & E staining, it can be determined that the liver tissue improved in the MCD groups with the use of L. CBG and not with H. CBG. For the 
Oil-Red staining, lipid accumulation can be described in the image by the white spaces. MCD has more lipid accumulation than the CTR groups and it can 
be noted that there is a slight decrease of lipid accumulation in the CBG treated groups.
Background:
❏ NAFLD- Non-Alcoholic Fatty Liver Disease; 
Cause still unknown; Risk Factors- Obesity, High 
Cholesterol
❏ NASH - Non-Alcoholic Steatohepatitis; Type of 
NAFLD; Most severe form of NAFLD; potential 
treatments exercise (lose weight) or vitamin E
❏ MCD- Methionine/Choline Diet; Model used for 
NASH-like symptom; High sucrose and fat diet
❏ CBG- Cannabigerol (CBG); Cannabinoid; 
❏ No research on this treatment in relation to 
NASH thus far. 
❏ Therefore, the purpose of this study is to see if 
there is a correlation between food consumption, 
liver and body weights of mice after CBG 
treatment upon being subjected to an MCD diet. 
Hypothesis: 
❏ This research aims to study the effects of CBG on 
MCD/Control diets on regulating the overall food 
consumption, body weight and liver weight. We 
predict that a low dosage of CBG will be most 
effective at reducing the symptoms of NASH.  
Figure 1. Average food consumption (A) and Liver to Body weight ratio (B) were obtained to evaluate the mices’ response to the various treatments. It can be 
deciphered that for food consumption, there was an increase in the amount of food consumed as the CBG dose increased and there was a p < 0.05 
significance when the CTR H. CBG was compared to the MCD. For the liver to body weight ratio, there was no significant correlation between any of the 





Figure 2. Shows the male body weight averages 
among the various treatment groups (C) and the 
average liver weights across the treatment 
groups (D). The body weights between CTR and 
MCD were highly significant as was the CBG 
treatments on both diets which is indicated at a p 
level of p < 0.0001. It can be seen that when 
treated with the MCD diet, there was a reduction 
in the liver weights. This reduction was 
minimized with the introduction of CBG 
treatment as seen in the H. CBG recovery of the 
liver loss. When comparing the CTR L. CBG to 
MCD L. CBG, there was a moderate significance 
at p < 0.01 and the other significances across 
CTR to MCD were just slightly significant at a    p 
< 0.05. 
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